ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.

Trial Details

NCT ID

NCT06195709

Phase

PHASE3

Sponsor

Institut Curie

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Endocrine therapy
Endocrine therapy combined with the local treatment of FES-negative lesions
Chemotherapy

Locations (sample)

Bayonne, France|43.49316,-1.473
Bordeaux, France|44.84124,-0.58046
Bordeaux, France|44.84124,-0.58046
Caen, France|49.18585,-0.35912
Dijon, France|47.31344,5.01391

Key Eligibility Criteria

Metastatic invasive breast carcinoma of no special type.
Females and males of age ≥18 years.
Life expectancy \> 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →